What is the recommended dosing regimen and duration for acyclovir suppressive therapy in patients with frequent recurrent genital herpes, including adjustments for renal impairment?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Acyclovir Suppressive Therapy

For patients with frequent recurrent genital herpes (≥6 recurrences per year), prescribe acyclovir 400 mg orally twice daily for chronic suppressive therapy, which reduces recurrence frequency by ≥75%. 1, 2

Recommended Dosing Regimen

Standard Suppressive Therapy

  • Acyclovir 400 mg orally twice daily is the established regimen 1, 2
  • Alternative: Acyclovir 200 mg orally 3-5 times daily (less convenient, use to find minimum effective dose for individual patients) 3

Duration of Therapy

  • Continue for up to 12 months, then reassess 2
  • After 1 year of continuous suppression, discontinue therapy temporarily to evaluate the patient's recurrence rate, as frequency naturally decreases over time in many patients 1
  • Safety and efficacy documented for up to 6 years of continuous use 1
  • Long-term suppression (up to 3 years) shows 61% of patients remain recurrence-free in year 3, with annual recurrence rates dropping from >12 to approximately 1.0 per year 4

Renal Impairment Adjustments

Dose modification is mandatory in renal impairment 2:

For 400 mg twice daily regimen:

  • CrCl >10 mL/min/1.73m²: 400 mg every 12 hours (no adjustment)
  • CrCl 0-10 mL/min/1.73m²: 200 mg every 12 hours

For 800 mg dosing (if used):

  • CrCl >25 mL/min/1.73m²: 800 mg every 4 hours, 5x daily
  • CrCl 10-25 mL/min/1.73m²: 800 mg every 8 hours
  • CrCl 0-10 mL/min/1.73m²: 800 mg every 12 hours

Dialysis Patients:

  • Hemodialysis: Administer an additional dose after each dialysis session (acyclovir half-life ~5 hours during dialysis with 60% plasma concentration decrease) 2
  • Peritoneal dialysis: No supplemental dose needed after interval adjustment 2

Special Populations

HIV-Infected Patients

  • Use twice-daily regimens only (acyclovir 400 mg BID or valacyclovir 500 mg BID) 5
  • Single daily dosing is inadequate for HIV-infected individuals
  • Suppressive therapy also decreases HIV concentration in plasma and genital secretions 5
  • Monitor renal function if patient has substantial renal impairment 5

Pregnancy

  • Acyclovir is the first-line choice (most safety data available) 5
  • For prophylaxis after 36 weeks gestation: 400 mg three times daily until delivery 6
  • Suppressive therapy in late pregnancy reduces need for cesarean section due to active lesions 5

Clinical Efficacy

Suppressive therapy provides substantial benefit:

  • Reduces recurrence frequency by 74-93% 7
  • 25% of patients receiving 3 years of suppression remain completely recurrence-free 4
  • Does NOT eliminate asymptomatic viral shedding or completely prevent transmission 1
  • Post-treatment recurrence rates remain lower than pre-treatment baseline 8

Important Caveats

Monitoring Requirements

  • No routine laboratory monitoring needed unless substantial renal impairment exists 5
  • Maintain adequate hydration 2
  • Monitor for nausea or headache (occasional side effects) 5

Treatment Failure

  • If recurrences occur during suppression, suspect inadequate dosing 9
  • Consider increasing to 200 mg four times daily if breakthrough occurs on twice-daily dosing 8
  • If lesions don't resolve within 7-10 days, suspect acyclovir resistance (obtain viral culture and susceptibility testing) 5

Patient Counseling

  • Acyclovir is NOT a cure 2
  • Transmission can still occur during asymptomatic viral shedding 1
  • Avoid sexual contact when lesions or prodromal symptoms present 2
  • Use condoms consistently with new or uninfected partners 1

Resistance Concerns

  • Clinically significant acyclovir resistance has NOT been associated with suppressive therapy in immunocompetent patients 1
  • Resistance more likely in immunocompromised patients 5

Dosing Algorithm Summary

  1. Confirm indication: ≥6 recurrences per year
  2. Check renal function: Adjust dose if CrCl <10 mL/min
  3. Start: Acyclovir 400 mg PO BID
  4. Reassess at 1 year: Discontinue temporarily to evaluate ongoing need
  5. If breakthrough recurrences: Consider increasing frequency to 200 mg 4x daily
  6. Long-term use: Safe for up to 6 years if clinically indicated

Related Questions

How long should aciclovir be taken for acute genital herpes outbreaks and for long‑term suppressive therapy?
For genital herpes, how long can aciclovir (acyclovir) suppress symptoms?
How effective is topical acyclovir cream for treating genital herpes?
I have had a herpes simplex outbreak for three days; should I still start antiviral medication?
What are the antiviral dosing regimens for primary, recurrent, and suppressive treatment of genital herpes simplex in an adult with normal renal function?
What interventions are included in occupational therapy for a child with attention‑deficit symptoms?
For a patient already receiving the maximum dose of their current inflammatory bowel disease therapy, which next medication is most likely to be effective and has the lowest risk of loss of response?
What intravenous antibiotic can be used as an equivalent to oral Macrobid (nitrofurantoin) for treating uncomplicated urinary tract infection?
What are the side effects of immunoglobulin therapy (intravenous immunoglobulin [IVIG] or subcutaneous immunoglobulin [SCIG])?
What is the next step in managing a 67‑year‑old chronic dialysis patient on amitriptyline who became psychotic and combative, received 250 mg intramuscular ketamine, is now asleep with a normal head CT, normal routine labs except markedly elevated serum creatinine, and is at a hospital without dialysis capability?
What antimicrobial regimen should be used to treat a carbapenem‑resistant Klebsiella pneumoniae infection and a concurrent Enterococcus faecalis infection?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.